President Edgars Rinkevics and Health Minister Hosams Abu Meri met on Monday to discuss expanding support solutions for patients with cancer and type 1 diabetes. The talks focused on the current system of state-funded medicines and medical devices, with an emphasis on increasing transparency and broadening patient access.
Improving Access to State-Funded Healthcare
During the meeting, President Rinkevics noted that the state-funded medicine system has undergone recent changes, including updated prescription procedures and a significant increase in budget funding. He emphasized the importance of listening to medical professionals and patient groups whose needs have not yet been addressed.
Health Minister Abu Meri briefed the president on efforts to identify health sector challenges to establish priority actions for the 2027-2030 period. Even as acknowledging progress in state-funded medicines, Abu Meri agreed that the system requires further transparency and more targeted support for patients.
Proposed Changes for Diabetes Care
The Health Ministry is exploring ways to provide glucose monitoring sensors to critical patient groups within the current year. Looking ahead to the 2027 budget, the ministry is advancing a proposal to provide 75 percent reimbursement for these sensors for all diabetic patients and insulin pumps for specific groups.
A dedicated task force has already agreed in principle to set compensation for monitoring sensors at 75 percent for patients aged 18 and older. This expansion could require an additional EUR 3.63 million from the 2027 state budget. The task force is also developing alternative solutions to identify priority groups if full funding is not allocated.
Future Outlook for Medical Device Compensation
Regarding insulin pumps, the task force intends to develop clear clinical criteria based on recommendations from the Latvian Association of Endocrinologists. Under optimal conditions, the state could potentially provide insulin pump therapy to between 100 and 200 patients annually.
Estimates suggest that providing insulin pumps to 100 additional patients in 2027 would cost approximately EUR 1.65 million. The Health Ministry will continue refining these funding scenarios to create a sustainable proposal for the compensation mechanism.
Frequently Asked Questions
Who currently receives state-provided continuous glucose monitors?
These monitors are currently provided to children under 18, patients after pancreatic resection, patients after organ transplantation, and pregnant or post-natal patients with type 1 or type 2 diabetes who are receiving insulin therapy.
What is the proposed reimbursement rate for glucose sensors for adults?
The task force has agreed in principle to a 75 percent compensation rate for monitoring sensors for patients aged 18 and older.
How will criteria for insulin pump compensation be determined?
Clear clinical criteria will be developed based on recommendations provided by the Latvian Association of Endocrinologists.
How should governments balance limited healthcare budgets with the need for specialized medical technology?
